All of Us Research Program
Do you want to change the future of health? The Froedtert & MCW health network is part of the National Institutes of Health All of Us Research Program. It has a simple mission — speed up health research breakthroughs. To do this, All of Us is asking one million people to share their health information. Learn how you can help make a difference by joining the All of Us Research Program.
155 results for "Cancer"
A Phase 0 Trial of HB-201 for Subjects with Transoral Resectable Human Papillomavirus 16 Positive (HPV 16+) Oropharynx Cancer or with Locally Advanced Cervical Cancer Treated with Chemotherapy and Radiation
To investigate how HB-201 affects the immune response
profiles in subjects with HPV 16+ head and neck cancer (HNC) and cervical cancer. To compare the immunologic response of HB-201 when it is administered as an IV or IT injection.
profiles in subjects with HPV 16+ head and neck cancer (HNC) and cervical cancer. To compare the immunologic response of HB-201 when it is administered as an IV or IT injection.
Protocol No
HOOKIPA-H-200-002
Sub Category
Phase I, First In Human Trial Evaluating BI 1387446 Alone And In Combination with BI 754091 in Solid Tumors
To characterize the safety and to determine the maximum tolerated dose (MTD) for BI 1387446 in combination with ezabenlimab (BI 754091).
Protocol No
BI-1426-0001
Composite Health Assessment Risk Model for Older Adults: Applying Pre-transplant Comorbidity, Geriatric Assessment and Biomarkers to Predict Non-Relapse Mortality after Allogeneic Transplantation in Older Adults
Composite Health Assessment Risk Model (CHARM) for Older Adults
Protocol No
CTN-1704
Sub Category
A Phase I Study of MR-Guided Dose-Escalated Hypofractionated Adaptive Radiation Therapy and Immunotherapy in Primary Metastatic or Very Locally Advanced Patients with Head and Neck Cancer
A Phase I Study of MR-Guided Dose-Escalated Hypofractionated Adaptive Radiation Therapy and Immunotherapy in Primary Metastatic or Very Locally Advanced Patients with Head and Neck Cancer
Protocol No
IIT-AWAN-NIH-DEHART
Sub Category
NCI COVID-19 in Cancer Patients Study (N-CCaPS): A Longitudinal Natural History Study
NCI COVID-19 in Cancer Patients, NCCAPS Study. How does COVID19 affect the outcomes of people undergoing cancer treatment? How does having cancer affect COVID-19?
Protocol No
NCI-COVID-NCCAPS
Treatment Free Remission After Combination Therapy with Ruxolitinib Plus Tyrosine Kinase Inhibitors in Chronic Phase Chronic Myeloid Leukemia (CP-CML) Patients Who Relapsed After a Prior Attempt at TKI Discontinuation
Treatment Free Remission After Combination Therapy With Ruxolitinib Plus Tyrosine Kinase Inhibitors
Protocol No
HJKC3-0002
Sub Category
Phase 1 Study of Redirected Autologous T Cells Engineered to Contain an Anti-CD19 and Anti-CD20 scFv Coupled to CD3-zeta; and 4-1BB Signaling Domains in Pediatric and Young Adult Patients with Relapsed and/or Refractory CD19 or CD20 B-cell Acute Lymphoblastic Leukemia
Phase 1 Study of CAR-20/19-T Cells in Pediatric and Young adult Patients with R/R B Cell ALL
Protocol No
IIT-TALANO-CART-ALL
Sub Category
A Phase II Study of Cabozantinib and Temozolomide in Patients with Unresectable or Metastatic Leiomyosarcoma and Other Soft Tissue Sarcomas
Cabozantinib and Temozolomide for the Treatment of Unresectable or Metastatic Leiomyosarcoma or Other Soft Tissue Sarcoma
Protocol No
NU-19S01
Sub Category
A Randomized Phase II Study of Gemcitabine and Nab-Paclitaxel Compared with 5-Fluorouracil, Leucovorin, and Liposomal Irinotecan in Older Patients with Treatment Naïve Metastatic Pancreatic Cancer (GIANT)
Comparing Two Treatment Combinations for Older Patients With Pancreatic Cancer That Has Spread
Protocol No
ECOG-EA2186-GIANT
Sub Category
Phase II Trial of Intravesical Gemcitabine and MK-3475 (Pembrolizumab) in the Treatment of Patients With BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
Addition of Pembrolizumab to Intravesical Chemotherapy (Gemcitabine) for the Treatment of NMIBC
Protocol No
ALLIANCE-A031803
Sub Category
Randomized Phase II Trial of Niraparib with Standard Combination Radiotherapy and Androgen Deprivation Therapy (ADT) in High Risk Prostate Cancer (With Initial Phase I)
Niraparib with Standard Combination RT & ADT in Treating Patients With High Risk Prostate Cancer
Protocol No
NRG-GU007
Sub Category
HistoSonics-CSP1427-HOPE4LIVER: The HistoSonics System for Treatment of Primary and Metastatic Liver Tumors Using Histotripsy (#HOPE4LIVER US)
HistoSonics System for Treatment of Primary & Metastatic Liver Tumors Using Histotripsy #HOPE4LIVER
Protocol No
HISTOSONICS-CSP1427-HOPE4LIVER
Sub Category
A Phase 1 Dose Escalation Study to Assess Safety and Efficacy of ADP-A2M4CD8 in HLA-A2+ Subjects with MAGE-A4 Positive Tumors
ADP-A2M4CD8 in HLA-A2+ Subjects with MAGE-A4 Positive Tumors
Protocol No
ADP-0055-001-MAGE-A4-SURPASS
A Phase II Randomized Trial of Radium-223 Dichloride and Cabozantinib in Patients With Advanced Renal Cell Carcinoma With Bone Metastasis (RadiCal)
Cabozantinib + New Anti-cancer Drug Radium-223 Dichloride for Advanced RCC that's Spread to the Bone
Protocol No
ALLIANCE-A031801-RADICAL
Sub Category
A Pivotal Trial Of Envafolimab, And Envafolimab In Combination With Ipilimumab, In Patients With Advanced Or Metastatic Undifferentiated Pleomorphic Sarcoma Or Myxofibrosarcoma Who Have Progressed On Prior Chemotherapy
Envafolimab And Envafolimab With Ipilimumab In Patients With Undifferentiated Pleomorphic Sarcoma Or Myxofibrosarcoma (ENVASARC)
Protocol No
TRACON-KN035SAR201-ENVASARC
Sub Category
The OVAL Study: A Randomized, Controlled, Double-Arm,Double-Blind, Multi-Center Study of Ofranergene Obadenovec (VB-111) Combined with Paclitaxel vs. Paclitaxel Combined with Placebo for theTreatment of Recurrent Platinum-Resistant Ovarian Cancer
To assess how well the combination of intravenous administration of VB-111 and paclitaxel compared to placebo and paclitaxel in patients with platinum resistant ovarian cancer as measured by Overall Survival.
Protocol No
GOG-3018-VBL-VB-111-701
Sub Category
MRI-ENHANCE MRI-Guided Adaptive Radiation Therapy for Organ Preservation in Rectal Cancer
This project is being done to to test an experimental treatment for your rectal adenocarcinoma called Magnetic Resonanceguided Adaptive Radiation Therapy in addition to the standard radiation therapy for your type of cancer.
Protocol No
IIT-HALL-MRI-ENHANCE
Sub Category
Testing the Addition of Radiation Therapy to the Usual Immune Therapy Treatment (Atezolizumab) for Extensive Stage Small Cell Lung Cancer, The RAPTOR Trial
Testing the addition of radiation therapy to the usual immune therapy treatment (atezolizumab) for patients with extensive stage small cell lung cancer
Protocol No
NRG-LU007
Sub Category
Tumor-Agnostic Precision Immunooncology and Somatic Targeting Rational for You (TAPISTRY) Phase II Platform Trial PLATFORM TRIAL
This study will evaluate the efficacy and safety of multiple therapies that are selected
using somatic alterations and potential predictive biomarkers identified via NGS assays
in patients with solid tumors.
using somatic alterations and potential predictive biomarkers identified via NGS assays
in patients with solid tumors.
Protocol No
HOFFMANN-BO41932-TAPISTRY
A Phase 2 Study of PacritiniB for Patients with BiochemicaL RelApse after Definitive Treatment for ProStaTe Cancer
This project is being done to test the effectiveness of a new drug called Pacritinib.
Researchers would also like to study how Pacritinib slows down the time until cancer
progression and assess its safety and tolerability.
Researchers would also like to study how Pacritinib slows down the time until cancer
progression and assess its safety and tolerability.
Protocol No
IIT-KILARI-J31001-BLAST
Sub Category